Hereditary Angioedema and the Advances in Treatment to Close the Gaps in Care

Hereditary Angioedema and the Advances in Treatment to Close the Gaps in Care

1.5 hour On-Demand Accredited Panel Discussion featuring a Patient Perspective Interview!

Moderator

Neil B. Minkoff, MD
Chief Medical Officer
Coeus Healthcare
Sudbury, Massachusetts

Faculty Panel

Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS
Professor of Pharmacy Practice
Creighton University School of Pharmacy and Health Professions

Professor of Medicine
Creighton University School of Medicine
Omaha, Nebraska

Marc Riedl, MD, MS
Professor of Medicine
Division of Rheumatology, Allergy & Immunology
Department of Medicine
University of California—San Diego (UCSD)

Clinical Director
US HAEA Angioedema Center at UCSD
La Jolla, California

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
Vice President, Clinical Programs and Services
WellDyne
Lakeland, Florida

Medical Writing Support

Lori Uildriks, PharmD, BCPS, BCGP
Clinical Pharmacist
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois
 
Program Description
Hereditary angioedema (HAE) is a serious disease of intermittent, recurrent, and potentially fatal swelling of the limbs, face, gastrointestinal tract, and airways. It can be classified into distinct subtypes, each with its own treatment course. Often, clinicians may misdiagnose HAE if it is suspected the patient’s presentation is linked to an allergic reaction from medication or food; in these occurrences, pharmacologic treatment options such as antihistamines, epinephrine, or glucocorticoids fail, indicating increased need for early diagnosis and access to effective treatment options. The recommended treatment approach includes a combination of agents for both acute attacks and prophylaxis. Long-term prophylaxis has the potential to offset significant costs spent in treating HAE acute attacks. These economic considerations are important for managed care pharmacists involved in the care of patients with HAE. This 3-part panel discussion will further examine diagnostic challenges and clinical presentation, specific treatment for different types of HAE, and protocols to facilitate access to new therapies for HAE. 

Target audience: Managed care pharmacists
Type of activity: Application
Release date: June 30, 2021
Expiration date: June 30, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Differentiate the various types of hereditary angioedema (HAE), the pathophysiology, and the burden of disease
• Dissect the challenges in diagnosing HAE and the various definitive laboratory tests
• Analyze the latest data on the efficacy, safety, and administration of current and emerging treatment options for HAE
• Examine the role of managed care professionals in the development of evidence-based clinical protocols

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-259-H01-P. The activity is available for CE credit through June 30, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Neil B. Minkoff, MD, has the following relevant financial relationships with commercial interests to disclose:
 

• Consultant: UCB, Novartis, Impel, Mass Association of Health Plans, Coeus Healthcare Consulting

Marc Riedl, MD, MS, has the following relevant financial relationships with commercial interests to disclose:
 

• Grant/Research Support: BioCryst, CSL Behring, Ionis, Kalvista, Pharvaris, Shire/Takeda
• Consultant: Adverum, Attune, BioCryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ionis, Kalvista, Pfizer, Pharming, Pharvaris, RegenexBio, Shire/Takeda, Spark
• Speakers Bureau: CSL Behring, Grifols, Pharming, Shire/Takeda

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty
Mark A. Malesker, PharmD, FCCP, FCCM, FASHP, BCPS
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP
 
Medical Writing Support
Lori Uildriks, PharmD, BCPS, BCGP

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Dipti Desai, PharmD, CHCP; Michelle C. Carlson, PharmD; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms